1	LEXINGTON LAW GROUP Mark N. Todzo, State Bar No. 168389	
2	Howard Hirsch, State Bar No. 213209	
3	Lisa Burger, State Bar No. 239676 1627 Irving Street	
4	San Francisco, CA 94122 Telephone: (415) 759-4111	
5	Facsimile: (415) 759-4112	
6	Attorneys for Plaintiff	
7	CENTER FOR ENVIRONMENTAL HEALTH	
8	SUDEDIOD COUDT OF THE	ΣΤΑΤΈ ΩΕ CALIEODNIA
9	SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SAN FRANCISCO	
10	COUNT FOF SAT	N FRAINCISCO
11		0N CCC 00 404227
12	CENTER FOR ENVIRONMENTAL HEALTH,) Case No.: CGC-09-494337
13	Plaintiff,	[PROPOSED] CONSENT JUDGMENTRE: CYPRESS MEDICAL GROUP LLC
14	V.	
15	BASIC INTERNATIONAL, INC. DBA BASIC	
16	MEDICAL INDUSTRIES, INC.; DASH MEDICAL GLOVES, INC.; AMMEX	
17	CORPORATION; BIG TIME PRODUCTS, LLC; BOSS MANUFACTURING COMPANY;)
18	GOLDMAX INDUSTRIES, INC.; PRO-STAT,)
19	INC.; RITE AID CORPORATION; and Defendant DOES 1 through 200, inclusive,	
20	Defendant.	
21)
22		
23		
24		
25		
26		
27		
28		
LA: 642846v1		
	[PROPOSED] CONSENT JUDGMENT RE: CYPRESS N	VIEDICAL OKOUP LLC - Case NO. COC-09-494337

1. INTRODUCTION

1.1 On November 10, 2009, Plaintiff the Center for Environmental Health ("CEH"), a non-profit corporation acting in the public interest, filed a complaint entitled *Center for Environmental Health v. Basic International, Inc. dba Basic Medical Industries, Inc., et al.,* San Francisco County Superior Court Case Number CGC-09-494337 (the "Action"), for civil penalties and injunctive relief pursuant to the provisions of Cal. Health & Safety Code § 25249.5, *et seq.* ("Proposition 65"). On December 22, 2009, CEH amended the Complaint to name Rite Aid Corporation as a defendant. On October 18, 2010 CEH amended the Complaint to name Cypress Medical Group LLC ("Defendant") as a defendant. CEH and Defendant are referred to herein individually as a "Party" and collectively as the "Parties."

1.2 Defendant is a corporation that employs 10 or more persons and manufactured, distributed and/or sold vinyl gloves (the "Products").

1.3 On or about August 4, 2009, CEH served Rite Aid Corporation and the appropriate public enforcement agencies with the requisite 60-day Notice alleging that Rite Aid Corporation was in violation of Proposition 65. On or about July 2, 2010, CEH served Defendant and the appropriate public enforcement agencies with the requisite 60-day Notice alleging that Defendant was in violation of Proposition 65 (the "Notice"). The Notice and the Complaint in the Action allege that Defendant exposes people who use or otherwise handle the Products to di(2-ethylhexyl) phthalate ("DEHP"), a chemical known to the State of California to cause cancer, birth defects and other reproductive harm, without first providing clear and reasonable warning to such persons regarding the carcinogenicity and reproductive toxicity of DEHP. After serving Defendant with the Notice, CEH was informed that Defendant was the supplier responsible for the Products sold by Rite Aid Corporation that were identified in CEH's August 4, 2009 notice to Rite Aid Corporation. The Notice and Complaint allege that Defendant's conduct violates Health & Safety Code § 25249.6, the warning provision of Proposition 65. Defendant disputes such allegations and asserts that all of its products are safe and comply with all applicable laws.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

1.4 For purposes of this Consent Judgment only, the Parties stipulate that this Court has jurisdiction over the subject matter of the violations alleged in CEH's Complaint and personal jurisdiction over Defendant as to the acts alleged in CEH's Complaint, that venue is proper in the County of San Francisco, and that this Court has jurisdiction to enter this Consent Judgment as a full and final resolution of all claims which were or could have been raised in the Complaint based on the facts alleged therein.

1.5 The Parties enter into this Consent Judgment pursuant to a settlement of certain disputed claims between the Parties as alleged in the Complaint. By executing this Consent Judgment, the Parties do not admit any facts or conclusions of law. It is the Parties' intent that nothing in this Consent Judgment shall be construed as an admission by the Parties of any fact, conclusion of law, issue of law or violation of law, nor shall compliance with the Consent Judgment constitute or be construed as an admission by the Parties of any fact, conclusion of law, or violation of law. Nothing in this Consent Judgment shall prejudice, waive or impair any right, remedy, argument or defense the Parties may have in this or any other or future legal proceedings.

2.

COMPLIANCE - REFORMULATION

2.1 Reformulation Standard – Removal of DEHP. After sixty (60) days following the entry of this Consent Judgment (the "Compliance Date"), Defendant shall not manufacture, distribute, ship, or sell, or cause to be manufactured, distributed or sold, any Product that contains in excess of trace amounts of DEHP. For purposes of this Consent Judgment only, "in excess of trace amounts" is more than 600 parts per million ("ppm"). In reformulating the Products to remove DEHP, Defendant may not use butyl benzyl phthalate ("BBP"), di-n-hexyl phthalate ("DnHP"), di-n-butyl phthalate ("DBP") or di-isodecyl phthalate ("DIDP") in excess of trace amounts. DEHP, BBP, DnHP, DBP and DIDP are together referred to herein as "Listed Phthalates."

2.2 Certification From Suppliers. Defendant shall issue specifications to its suppliers requiring that the Products shall not contain DEHP or any other Listed Phthalate in excess of trace amounts. Defendant shall obtain written certification from its suppliers of the

Products certifying that the Products do not contain any Listed Phthalate in excess of trace amounts.

2.3 Defendant's Testing. In order to ensure compliance with the requirements of Section 2.1, Defendant shall cause to be conducted testing to confirm that Products sold do not contain any Listed Phthalate in excess of trace amounts. Testing shall be conducted in compliance with Section 2.1. All testing pursuant to this Section shall be performed by an independent laboratory in accordance with one of the following test protocols: (1) EPA SW8270C and EPA SW3580A, (2) ASTM D3421-75, (3) or ARDL1AUTO Gas Chromatography/Mass Spectrometry as set forth in the protocol attached hereto as Exhibit A (referred to collectively as the "Test Protocols"). At the request of CEH, the results of the testing performed pursuant to this section shall be made available to CEH on a confidential basis.

2.3.1 Testing Frequency. For each of the first two orders of Products purchased from each of Defendant's suppliers after the Compliance Date, Defendant shall randomly select and test one glove from each of the greater of 0.1% (one-tenth of one percent) or eight, but in no case more than ten, of the total boxes of Products purchased from each supplier of the Products intended for sale. For a period of two years following the completion of the testing of the first two orders as described above, Defendant shall randomly select and test, from each supplier, as follows: for at least one purchase order every six months, one glove from each of the greater of 0.05% (one-twentieth of one percent) or four, but in no case more than five, of the total boxes of Products the total boxes of Products in that purchase order.

2.3.2 Products That Contain Listed Phthalates Pursuant to Defendant's Testing. If the results of the testing required pursuant to Section 2.3 show Listed Phthalates in excess of trace amounts in a Product, Defendant shall: (1) refuse to accept all of the Products that were purchased under the particular purchase order tested; (2) send a notice to the supplier explaining that such Products do not comply with the suppliers' certification; and (3) apply the testing frequency set forth in Section 2.3.1 as though the next shipment from the supplier were the first one following the Compliance Date. 2.4 Confirmatory Testing by CEH. CEH intends to conduct confirmatory testing of the Products. Any such testing shall be conducted by CEH at an independent laboratory, in accordance with any of the Test Protocols. In the event that CEH's testing under any of the Testing Protocols demonstrates that the Products contain Listed Phthalates in excess of trace amounts subsequent to the Compliance Date, CEH shall inform Defendant in a reasonably prompt manner of the test results, including information sufficient to permit Defendant to identify the Product(s). Defendant shall, within 30 days following such notice, provide CEH, at the address listed in Section 11.1, with the certification and testing information demonstrating its compliance with Sections 2.2 and 2.3 of this Consent Judgment. If Defendant fails to provide CEH with information demonstrating that it complied with Sections 2.2 and/or 2.3, Defendant shall be liable for stipulated payments in lieu of penalties for Products for which CEH produces tests demonstrating the presence of Listed Phthalates in excess of trace amounts in the Products. The payments shall be made to CEH and used for the purposes described in Section 3.1.

2.4.1 Stipulated Payments In Lieu of Penalties. If stipulated payments in lieu of penalties are warranted under Section 2.4, the stipulated payment amount shall be as follows for each Occurrence of Defendant selling a Product containing Listed Phthalates in excess of trace amounts after the Compliance Date:

First Occurrence:	\$500
Second Occurrence:	\$750
Third Occurrence:	\$1,000
Thereafter:	\$2,500

In the event that Defendant provides information, in accordance with Section 2.4, that it believes demonstrates its compliance with Sections 2.2 and 2.3 of the Consent Judgment, and CEH disputes such a claim, CEH shall have the burden of demonstrating that stipulated penalties are warranted by proving noncompliance with Sections 2.2 and 2.3 by a preponderance of the evidence. As used in this Section 2.4.1, the sale of any number of Products from a single lot shall constitute an "Occurrence," provided however that if Products from more than one lot are tested, or are collected for testing, by or on behalf of CEH under Section 2.4 during the same

Testing Period and are subject to stipulated penalties in this Section 2.4.1, all of those Products shall fall within a single Occurrence. As used this Section 2.4.1, a "Testing Period" refers to a period of 60 days or less.

2.5 Products in the Stream of Commerce. Any Products that have been manufactured, distributed, shipped, or sold, or that are otherwise in the stream of commerce prior to the Compliance Date shall be released from any claims that were brought or that could be brought by CEH in the Complaint, as though they were Covered Claims within the meaning of Section 7.1. As a result, the obligations of this Section 2 do not apply to such Products.

3.

SETTLEMENT PAYMENTS

3.1 Penalty. Defendant shall pay to CEH \$2,500 as a penalty pursuant to Health and Safety Code § 25249.7(b). CEH shall apportion such payment in accordance with Health and Safety Code §25249.12.

3.2 Monetary Payment in Lieu of Penalty. Defendant shall pay to CEH \$12,000 in lieu of any additional penalty pursuant to Health and Safety Code § 25249.7(b). CEH shall use such funds to continue its work protecting people from exposures to toxic chemicals. As part of this work, CEH intends to conduct periodic testing of the Products as set forth in Section 2.4. The payment required under this Section shall be made payable to CEH

3.3 Attorneys' Fees and Costs. Defendant shall pay \$25,500 to reimburse CEH and its attorneys for their reasonable investigation fees and costs, attorneys' fees, and any other costs incurred as a result of investigating, bringing this matter to Defendant's attention, litigating and negotiating a settlement in the public interest. The payment required under this Section shall be made payable to Lexington Law Group.

3.4 Delivery of Payments. All payments made pursuant to this Section 3 shall be delivered to the Lexington Law Group at the address set forth in Section 11.1 and shall be delivered within 10 days of entry of this Consent Judgment.

4. MODIFICATION OF CONSENT JUDGMENT

4.1 This Consent Judgment may be modified by written agreement of CEH and Defendant, or upon motion of CEH or Defendant as provided by law. Grounds for such

1

[PROPOSED] CONSENT JUDGMENT RE: CYPRESS MEDICAL GROUP LLC - Case No. CGC-09-494337

modification include, but are not limited to, any change in law that would (1) render Proposition 65 inapplicable to the Products or to DEHP, or (2) establish a compliance standard that would allow concentrations of DEHP and/or any Listed Phthalate in the Products to exceed 600 ppm without a Proposition 65 warning.

5.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

ENFORCEMENT OF CONSENT JUDGMENT

5.1 CEH may, by motion or application for an order to show cause, enforce the terms and conditions contained in this Consent Judgment. Should CEH prevail on any such motion, it shall be entitled to recover its reasonable attorneys' fees and costs associated with enforcing the Consent Judgment.

6.

7.

APPLICATION OF CONSENT JUDGMENT

6.1 This Consent Judgment shall apply to and be binding upon the Parties hereto, their divisions, subdivisions, parents and subsidiaries, and the successors or assigns of any of them.

CLAIMS COVERED AND RELEASE OF CLAIMS

7.1 This Consent Judgment is a full, final and binding resolution between CEH and Defendant of any violation of Proposition 65 that was or could have been asserted in the Complaint against Defendant (including any claims that could be asserted in connection with any of the Products covered by this Consent Judgment) or its parents, subsidiaries or affiliates, divisions, and all of their directors, officers, employees, agents, attorneys, distributors, wholesalers, retailers (including but not limited to Rite Aid Corporation), or customers (collectively, "Defendant Releasees") based on failure to warn about alleged exposures to DEHP resulting from any Products manufactured, distributed or sold by Defendant ("Covered Claims") on or prior to the date of entry of this Consent Judgment. CEH, its directors, officers, employees and attorneys hereby release all Covered Claims against Defendant Releasees. Compliance with the terms of this Consent Judgment constitutes compliance with Proposition 65 with regard to exposures to Listed Phthalates from the Products.

7.2 Within 10 days of entry of this Consent Judgment, CEH shall file a request for dismissal of the action without prejudice as to Rite Aid Corporation in the case 28

entitled Center for Environmental Health v. Basic International, Inc. dba Basic Medical 1 2 Industries, Inc., et al., San Francisco Superior Court Case Number CGC 09-494337. 8. **SEVERABILITY** 3 8.1 In the event that any of the provisions of this Consent Judgment are held 4 5 by a court to be unenforceable, the validity of the enforceable provisions shall not be adversely affected. 6 9. **GOVERNING LAW** 7 9.1 The terms of this Consent Judgment shall be governed by the laws of the 8 State of California. 9 10. **RETENTION OF JURISDICTION** 10 10.1 This Court shall retain jurisdiction of this matter to implement and enforce 11 the terms this Consent Judgment. 12 11. **PROVISION OF NOTICE** 13 All notices required pursuant to this Consent Judgment and correspondence 14 11.1 15 shall be sent to the following: For CEH: 16 17 Mark N. Todzo Lexington Law Group 18 1627 Irving Street San Francisco, CA 94122 For Defendant: 19 Trenton H. Norris 20 Arnold & Porter LLP 275 Battery Street, Suite 2700 21 San Francisco, CA 94111 22 12. **COURT APPROVAL** 23 12.1 CEH will comply with the settlement notice provisions of Health and Safety 24 Code § 25249.7(f) and Title 11 of the California Code of Regulations § 3003. If this Consent 25 Judgment is not approved by the Court, it shall be of no force or effect. 26 27 28 - 7 -[PROPOSED] CONSENT JUDGMENT RE: CYPRESS MEDICAL GROUP LLC - Case No. CGC-09-494337

1
2
3
4
-
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

13. EXECUTION AND COUNTERPARTS

13.1 The stipulations to this Consent Judgment may be executed in counterparts and by means of facsimile, which taken together shall be deemed to constitute one document.

14. AUTHORIZATION

14.1 Each signatory to this Consent Judgment certifies that he or she is fully authorized by the Party he or she represents to stipulate to this Consent Judgment and to enter into and execute the Consent Judgment on behalf of the Party represented and legally bind that Party. The undersigned have read, understand and agree to all of the terms and conditions of this Consent Judgment. Except as explicitly provided herein, each Party is to bear its own fees and costs.

AGREED TO:

CENTER FOR ENVIRONMENTAL HEALTH

15	Cui	Dated: $2/3/.1$
16	Charlie Pizarro, Associate Director	
17	CYPRESS MEDICAL GROUP LLC	
18	\cap	
19	(ductor	
20		Dated: 2/1/11
21	Andrew K. Birken [Name]	
22		
23	President [Title]	
24		
25		
26		
27		
28		
	- 8 -	
	[PROPOSED] CONSENT JUDGMENT RE: CYPRESS M	EDICAL GROUP LLC - Case No. CGC-09-494337

1	ORDER AND JUDGMENT
2	Based upon the stipulated Consent Judgment between CEH and Cypress Medical
3	Group LLC, the settlement is approved and the clerk is directed to enter judgment in accordance
4	with the terms herein.
5	
6	Dated:
7	Judge, Superior Court of the State of California
8	sudge, superior court of the state of cultorina
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
	- 9 - [PROPOSED] CONSENT JUDGMENT RE: CYPRESS MEDICAL GROUP LLC - Case No. CGC-09-494337

1	EXHIBIT A
2	• Sample as received from customer is ground or cut into small pieces.
3	• Approximately 1g of sample is weighed out to the nearest 0.1 mg.
4	• Per ASTM D297, sample is extracted in ethyl ether for 16 hours at reflux temperature.
5	• Sample extract is dried and quantitatively reconstituted to the appropriate level with
6	chloroform and placed into GC/MS vial.
7	• Sample extract is analyzed by GC/MS technique.
	• Chemicals that are targeted for quantification are identified in each sample chromatogram
8	and their peaks integrated for area determination.
9	• Past controls of specified concentrations of target chemicals are observed and used as a
10	guideline for the preparation of new controls.
11	• Three or more new controls of known concentration level are prepared for each
12	concentration range to establish the appropriate quantification/calibration curve.
13	• The quantification curves, encompassing the low and high unknown sample chemical concentrations, are then used to calculate the concentration of targeted chemicals in each
14	sample.
15	Sumpro.
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
23 26	
27	
28	
	- 10 -
	[PROPOSED] CONSENT JUDGMENT RE: CYPRESS MEDICAL GROUP LLC - Case No. CGC-09-494337